Advertisement
Table 1 Patient characteristics (n = 44)
| Median age, years (range) | 71 (49–86) |
|---|---|
| Gender Male/female | 19/25 |
| Performance status | |
| 0 | 24 (54.5) |
| 1 | 14 (31.8) |
| 2 | 4 (9.1) |
| ≥3 | 2 (4.5) |
| Type of M protein n (%) | |
| IgG | 22 (50.0) |
| IgA | 10 (22.7) |
| IgD | 1 (2.3) |
| BJP | 10 (22.7) |
| No secreted | 1 (2.3) |
| Durie-Salmon stage n (%) | |
| I | 4 (9.1) |
| II | 6 (13.6) |
| III | 34 (77.3) |
| ISS stage n (%) | |
| 1 | 10 (22.7) |
| 2 | 11 (25.0) |
| 3 | 23 (52.3) |
| No. genetic abnormalities of 13q deletion n (%) | |
| Yes | 6 (13.6) |
| No | 38 (86.4) |
| No. of stem cell transplantation n (%) | |
| Yes | 15 (34.1) |
| No | 29 (65.9) |
| No. of prior treatment regimens* n (%) 09 (20.5) | |
| 1 | 16 (36.4) |
| 2 | 7 (15.9) |
| ≥3 | 12 (27.3) |
| Type of prior treatment regimens n (%) | |
| VAD | 22 (25.9) |
| MP | 19 (22.4) |
| HDD | 10 (11.8) |
| Thalidomide | 9 (10.6) |
| Stem cell transplantation | 5 (5.9) |
| CP | 5 (5.9) |
| ROAD | 4 (4.7) |
| Cyclophosphamide alone | 3 (3.5) |
| DEX pulse | 2 (2.4) |
| MD | 2 (2.4) |
| INF α-MP | 2 (2.4) |
| CAD | 1 (1.2) |
| RD | 1 (1.2) |
